CYTK vs REGN · rev $88.0M vs P/E 14, rev $14.34B
Cytokinetics Inc (CYTK) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CYTK revenue for 2025-12-31 was $88.0M. Net income was -$785.0M. Revenue was up 376.6% from 2024-12-31 to 2025-12-31. CYTK currently screens at market cap $4.05B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CYTK currently screens at market cap $4.05B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CYTK and REGN stock pages for the full models.
Not investment advice.